Cantor Fitzgerald Reiterates Overweight Rating on Aquestive Therapeutics (AQST) Sep 10, 2026 09:31AM
Aquestive Therapeutics secures $150 million debt facility with Oaktree May 12, 2026 09:31AM
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree May 12, 2026 09:31AM
Cantor Fitzgerald Reiterates Overweight Rating on Aquestive Therapeutics (AQST) Aug 19, 2025 07:01AM
Aquestive Therapeutics prices $85 million stock offering Aug 14, 2025 06:28AM


Aug 14, 2025 06:28AM Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
Aug 14, 2025 06:01AM Aquestive secures $75 million funding from RTW for Anaphylm launch
Aug 14, 2025 06:00AM Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylmâ„¢ (epinephrine) Sublingual Film
Dec 17, 2024 06:31AM Cantor Fitzgerald Starts Aquestive Therapeutics (AQST) at Overweight